Elevance Health, Inc.
Elevance Health, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Elevance Health, Inc. Q2 FY26 key numbers
- Revenue
- Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026.
As stated in Elevance Health, Inc.'s Q2 FY26 earnings call transcript · published 29 May 2026. Reported figures, not investment advice.
The short version
- Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026 (Page 16). - Elevance Health expects at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75.
From Elevance Health, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026 (Page 16).
- Growth driven by margin expansion opportunities across most end markets and benefits from AI investments and prudent pricing strategies (Page 16).
- Multiple independent earnings levers in motion since 2025, including pricing, care management, and portfolio positioning (Page 16).
- Meaningful investments in 2026 expected to mature and boost returns in 2027 (Page 16).
- Strong national account sales momentum, including marquee wins and nearly 100% renewals, supported by integrated medical and pharmacy capabilities (Pages 4, 5, 9).
- Continued pipeline strength in employer markets and increasing consolidation of clients under single carrier arrangements (Pages 4, 9).
2 more points from Elevance Health, Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Elevance Health, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Elevance Health is investing more than $1 billion in digital and AI-enabled capabilities to support their strategy of improving affordability, simplifying healthcare, and personalizing member experience.
- Investments are focused on embedding AI across clinical, operational, and administrative workflows to improve engagement, cost management, predictive analytics, and reduce administrative expenses through automation.
- Meaningful investments are being made in 2026, expected to mature and deliver returns contributing to earnings growth in 2027.
- Strategic investments support the scaling of Carelon’s risk-based solutions, including oncology, post-acute, and behavioral health programs.
2 more points from Elevance Health, Inc.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Elevance Health, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Elevance Health, Inc.'s call on order book
Create a free account to keep reading this call
What the Q2 FY26 call signalled
1 of 3 strong
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- DaVita Inc. (Q2 FY26)
DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Elevance Health, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Elevance Health, Inc. Q2 FY26 results?
- Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026 (Page 16). - Elevance Health expects at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75.
What is Elevance Health, Inc. share price analysis?
Elevance Health, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 16.4 with a market cap of $85,291. Investors should review the full earnings analysis for detailed insights.
Is Elevance Health, Inc. planning capital expenditure?
- Elevance Health is investing more than $1 billion in digital and AI-enabled capabilities to support their strategy of improving affordability, simplifying healthcare, and personalizing member experience.
Keep Elevance Health, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.